Zimmer Biomet Holdings Inc. Q1 Profit Climbs

Zimmer Biomet reported first-quarter GAAP earnings of $238.1 million, or $1.22 per share, up from $182.0 million, or $0.91 per share, a year ago. Revenue rose 9.5% to $2.08 billion, while adjusted EPS came in at $2.09. The company also guided full-year EPS to $8.40-$8.55 and revenue growth to 2.5%-4.5%.

Analysis

ZBH’s beat-plus-raise is more important for the orthopedic capital cycle than for the headline earnings print. The key signal is that the recovery is broad enough to support both margin leverage and a higher growth floor, which tends to favor the larger installed-base players first: as elective volumes normalize, the companies with the deepest surgeon relationships and broadest implant portfolios usually capture disproportionate share before smaller peers can respond. That creates a secondary tailwind for distributors and service partners, but a tougher backdrop for subscale device names that rely on pricing rather than mix.

The market is likely underappreciating the durability of the guidance range. A 2.5%-4.5% revenue outlook implies management sees the current demand environment as sustainable, not just a one-quarter backlog catch-up; that matters because ortho demand is lumpy and investors typically over-discount any single quarter as being beneficiary of timing. If this reflects better procedure conversion rather than one-off channel fill, the implication is that consensus numbers for the next two quarters may still be too low, especially on operating leverage.

The contrarian risk is that the stock may already be pricing a clean recovery while the next leg depends on execution, not demand. Any sign of higher promotion spending, surgeon rebate pressure, or margin normalization from input-cost inflation would cap the multiple expansion even if revenue holds up. The biggest reversal risk is a slowdown in elective procedures over the next 1-2 quarters, since ortho is one of the few healthcare verticals where macro sensitivity can show up quickly in utilization data.

Key Decisions for Investors

• Go long ZBH on a 1-3 month horizon if it trades near post-earnings support rather than gap-up highs; the setup is favorable for estimate revisions, but chase risk is high after a clean beat.
• Pair trade: long ZBH / short a lower-quality orthopedic peer with weaker scale and pricing power over the next 1-2 quarters; the second-order thesis is share capture as procedure volumes normalize.
• Sell downside puts on ZBH expiring in 6-10 weeks if implied volatility stays elevated; the earnings-quality signal supports premium capture, but only with defined risk and a strike below the current consolidation range.
• For investors already long medtech, rotate marginal exposure toward ZBH from slower-growth hospital-capex names over the next month; this is a cash-flow and revision story, not a broad healthcare beta trade.
• Set a catalyst watch for the next procedure-volume data and commentary on pricing discipline; if either weakens, trim quickly because the stock’s upside case is most vulnerable to margin-compression surprises.